Orion
48.85
EUR
-1.05 %
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
13,906 following
-1.05%
+14.19%
+15.62%
+2.56%
+24.02%
+13.29%
+35.32%
+11.05%
+335%
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Read moreMarket cap
6.89B EUR
Turnover
7.7M EUR
P/E (adj.) (24e)
20.85
EV/EBIT (adj.) (24e)
16.48
P/B (24e)
6.92
EV/S (24e)
4.45
Dividend yield-% (24e)
3.38 %
Financial calendar
25.2
2025
Annual report '24
3.4
2025
General meeting '25
23.4
2025
Interim report Q1'25
Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting
Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orion and Marinus terminate agreement for ganaxolone in Europe
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Drug development investment: Value creation through M&As and licensing agreements
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
Regulation of drug development
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
142,701 Orion Corporation A shares converted into B shares
Orion Research Foundation grants EUR 1,109,000 for research in 2025
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
Orion Corporation: Managers’ transactions – Henrik Stenqvist
